665 related articles for article (PubMed ID: 19436018)
21. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Kunutsor SK; Seidu S; Khunti K
Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
[TBL] [Abstract][Full Text] [Related]
22. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
23. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
Anand SS; Yusuf S
JAMA; 1999 Dec; 282(21):2058-67. PubMed ID: 10591389
[TBL] [Abstract][Full Text] [Related]
24. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
Lee IM; Cook NR; Gaziano JM; Gordon D; Ridker PM; Manson JE; Hennekens CH; Buring JE
JAMA; 2005 Jul; 294(1):56-65. PubMed ID: 15998891
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
26. Rationale for the use of platelet aggregation inhibitors in PAD patients.
Agnelli G
Vasc Med; 2001; 6(3 Suppl):13-5. PubMed ID: 11789961
[TBL] [Abstract][Full Text] [Related]
27. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Poredos P; Jezovnik MK
Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials.
Li X; Zhou G; Zhou X; Zhou S
J Neurol Sci; 2013 Sep; 332(1-2):92-6. PubMed ID: 23871093
[TBL] [Abstract][Full Text] [Related]
29. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Stroke; 2003 Aug; 34(8):2072-80. PubMed ID: 12855826
[TBL] [Abstract][Full Text] [Related]
30. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
Lancet; 2006 May; 367(9523):1665-73. PubMed ID: 16714187
[TBL] [Abstract][Full Text] [Related]
31. Antiplatelet therapy in peripheral arterial disease.
Aronow WS
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Sep; 4(3):265-7. PubMed ID: 15379619
[TBL] [Abstract][Full Text] [Related]
32. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
Fowkes FG; Price JF; Stewart MC; Butcher I; Leng GC; Pell AC; Sandercock PA; Fox KA; Lowe GD; Murray GD;
JAMA; 2010 Mar; 303(9):841-8. PubMed ID: 20197530
[TBL] [Abstract][Full Text] [Related]
33. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
Guirguis-Blake JM; Evans CV; Senger CA; O'Connor EA; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):804-13. PubMed ID: 27064410
[TBL] [Abstract][Full Text] [Related]
34. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
Xie M; Shan Z; Zhang Y; Chen S; Yang W; Bao W; Rong Y; Yu X; Hu FB; Liu L
PLoS One; 2014; 9(10):e90286. PubMed ID: 25360605
[TBL] [Abstract][Full Text] [Related]
35. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
36. [Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review].
Tang HQ; Yang LL; Hu SL; Shen G; Sun YH; Huang XH; Li JH; Xu TJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Apr; 38(4):315-20. PubMed ID: 20654075
[TBL] [Abstract][Full Text] [Related]
37. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ
JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
[TBL] [Abstract][Full Text] [Related]
38. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
[TBL] [Abstract][Full Text] [Related]
39. Aspirin for prevention of stroke and cardiovascular events among patients with peripheral artery disease.
Takagi H; Umemoto T
JAMA; 2009 Sep; 302(11):1165; author reply 1165-6. PubMed ID: 19755690
[No Abstract] [Full Text] [Related]
40. A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease.
Qian J; Yang XH
Medicine (Baltimore); 2015 Aug; 94(31):e1293. PubMed ID: 26252306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
